- The
new version of the DehydraTECH delivery platform is suitable for use in
pills, capsules and tablets for the pharmaceutical, medical and supplement
markets
- DehydraTECH
has demonstrated that it can deliver eight times more CBD into the blood
than standard industry formulations
- Animal
testing shows that combining DehydraTECH with a nanoemulsion formulation
greatly assists delivery of cannabinoids and nicotine across the
blood-brain barrier
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new
enhanced version of its patented delivery technology, DehydraTECH, has
demonstrated that it can deliver eight-times more CBD into the blood and
19-times more CBD into the brain tissue than standard industry formulations.
These results were confirmed in clinical lab tests conducted with live animals.
LXRP has filed new patent applications based on these innovations (http://ibn.fm/5y9TR).
The new DehydraTECH delivery platform is ideally suited for
solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical,
medical and supplement markets.
LXRP intends to perform more studies on the enhanced
DehydraTECH and focus on optimizing implementation regarding product
applications for its licensees.
In earlier test results, LXRP announced that original or standard
DehydraTECH combined with generic nanotech techniques delivers 1,137 percent
more cannabidiol (CBD) into animal brain tissue following oral ingestion than
certain existing industry formulations (http://ibn.fm/kxoTG). The tests consisted of oral
administration of CBD into 10 male Sprague-Dawley rats.
In animal tests conducted in 2018 and 2019, results showed
that DehydraTECH greatly assisted in the delivery of drugs, including nicotine
and cannabinoids, across the blood-brain barrier. The demonstrated
effectiveness of DehydraTECH, combined with nanoemulsification, significantly
expands the application of the technology for conventional dosage forms,
consumable liquids and beverage dosage forms.
LXRP is a Canadian bioscience company and a drug-delivery
platform innovator. The company out-licenses its disruptive delivery
technology, DehydraTECH. The technology is designed to promote healthier
ingestion methods and lower overall dosing. Lexaria is the only company
globally to have a patent issued for the oral delivery of all cannabinoids.
DehydraTECH has received patents in the United States and Australia, and has
multiple patents pending in more than 40 countries worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from start-ups
to established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
